Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Pfizer’s Cancer Research Selected for Feasibility Study under AMED Program; Applied Jointly with Mie Univ. and Other Partners
October 13, 2016
- Interview: Teva Exec Says Takeda JV Can Grow Profit despite Generic Price Declines
October 12, 2016
- Takeda, UK’s Crescendo Cut Collaboration Deal on Cancer Therapeutics
October 12, 2016
- Daiichi Sankyo’s ADC DS-8201a Well-Tolerated in PI
October 12, 2016
- There Will Be Consolidation in Japan Generic Space: Teva Exec
October 11, 2016
- Teva-Takeda JV Eyes Top Spot in Off-Patent Drug Market: CEO
October 11, 2016
- Astellas Suits Actavis Elizabeth in US over Myrbetriq Patent
October 11, 2016
- Companion Diagnostics for Opdivo, Keytruda Pending Approval: Agilent Japan Head
October 7, 2016
- Santen, RIKEN, FBRI Sign Drug Discovery Deal for Retinal Disease
October 7, 2016
- Teikoku Seiyaku, Mitsubishi Tanabe Hook Up on Sales of Anti-Allergy Agents
October 6, 2016
- GHIT Fund to Invest 1.1 Billion Yen in Development of Neglected Disease Drugs
October 6, 2016
- Eurofarma Gets Latin American Rights to Eisai’s Cancer Candidate Farletuzumab
October 5, 2016
- Daiichi Sankyo, AgonOx Ink Immuno-Oncology Research Collaboration
October 5, 2016
- Marc van der Heijden to Lead Allergan Japan
October 4, 2016
- Daiichi Sankyo Launches Large-Scale Research in Elderly NVAF Patients
October 4, 2016
- Constipation Drug Delivers Positive PIII Data in Japan: EA Pharma, Mochida
October 4, 2016
- Mitsubishi Tanabe Looks to Double Late-Stage Pipelines; Faster Decisions Hold Key in Curbing Costs
October 3, 2016
- Data Out to Support Long-Term Use of Entyvio: Takeda
October 3, 2016
- Eisai to Kick Off Global PIII for Lenvatinib as First-Line RCC Therapy
October 3, 2016
- Mochida to Solely Distribute Janssen’s Pain Drug Tramcet from January
October 3, 2016
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…